Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686041 | 0.84 | HTR7 (0.54) | HTR7HRH4ADRA1DHTR2CADRA1A | |
| SCHEMBL2844731 | 0.79 | ABL1 (0.52) | HTR7HRH4ADRA1DHTR2CADRA1A | |
| SCHEMBL6081798 | 0.79 | HRH4 (0.44) | HTR7HRH4ADRA1DHTR2CADRA1A | |
| SCHEMBL12411106 | 0.76 | ABL1 (0.50) | HTR7HRH4ADRA1DHTR2CADRA1A | |
| SCHEMBL28157922 | 0.76 | CXCR4 (0.51) | HTR7HRH4STK17AHRH3CXCR4 | |
| SCHEMBL21364894 | 0.75 | STK17A (0.64) | STK17ALCK | |
| SCHEMBL6081834 | 0.74 | STK17A (0.47) | HTR7HRH4ADRA1DHTR2CADRA1A | |
| SCHEMBL6080832 | 0.74 | HTR7 (0.42) | HTR7HRH4ADRA1DHTR2CADRA1A | |
| Carbamic Acid SCHEMBL2847023 | 0.73 | ABL1 (0.48) | HTR7HRH4ABL1LCKCSF1R | |
| SCHEMBL19033878 | 0.73 | HRH4 (0.81) | HRH4HRH3TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675830-A4 | HETEROCYCLIC AMIDES AND SULFONAMIDES | SCIOS INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | SCIOS, INC. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1675830-A2 | HETEROCYCLIC AMIDES AND SULFONAMIDES | SCIOS INC. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005033072-A2 | HETEROCYCLIC AMIDES AND SULFONAMIDES | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | MAP4K2, MAP3K8, MAP3K2 | HTR7 1715/4885HRH4 966/4885ADRA1D 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.